HIPRA is a biotechnological pharmaceutical company focused on prevention for animal and human health, with a broad range of highly innovative vaccines. With its claim “Building immunity for a healthier world”, HIPRA affirms its commitment to contributing with solutions that improve world health.
HIPRA has a solid international presence in more than 40 countries, with its own subsidiaries, 3 R+D centres and 6 production centres strategically located in Europe (Spain) and America (Brazil).
Moreover, its extensive international distribution network keeps open marketing channels with nearly 100 other countries, thereby covering the 5 continents.
Research and Development constitute the core of its knowledge. HIPRA dedicates 10% of its annual turnover to R&D activities that concentrate on the creation and application of the latest scientific advances to the development of the highest quality innovative vaccines. To give added value to its vaccination experience, the company also develops medical devices and traceability services.
HIPRA performs and monitors all the production stages of its services and biological products in its facilities, which are equipped with the latest technological advances. HIPRA is the company that has launched the most biotech vaccines in the last 10 years, with a total of 22 vaccines.
HIPRA is ranked 6th of the global leaders in the veterinary industry developing vaccines for Animal Health.